Regeneron Pharmaceuticals (REGN) Share-based Compensation (2009 - 2026)

Regeneron Pharmaceuticals has reported Share-based Compensation for 18 years, with the latest figure at $243.0 million in Q2 2026.

• On a quarterly basis, Share-based Compensation fell 3.46% year-over-year to $243.0 million in Q2 2026; TTM through Jun 2026 was $986.7 million, a 12.0% increase from a year earlier, with the FY2025 full-year figure at $993.7 million, down 3.44% from the prior year.
• Share-based Compensation was $243.0 million for Q2 2026 at Regeneron Pharmaceuticals, down from $257.4 million in the prior quarter.
• The five-year high for Share-based Compensation was $343.7 million in Q1 2024, with the low at $120.2 million in Q3 2024.
• Average Share-based Compensation over 5 years is $229.6 million, with a median of $239.6 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation slumped 60.16% in 2022, then soared 97.17% in 2025.
• Over 5 years, Share-based Compensation stood at $232.0 million in 2022, then grew by 3.62% to $240.4 million in 2023, then climbed by 5.41% to $253.4 million in 2024, then fell by 1.62% to $249.3 million in 2025, then fell by 2.53% to $243.0 million in 2026.
• The last three Share-based Compensation figures came in at $243.0 million (Q2 2026), $257.4 million (Q1 2026), and $249.3 million (Q4 2025), per Business Quant data.